top of page

Amarex Taiwan is an affiliate of Amarex Clinical Research,

a full-service, international CRO with extensive experience successfully performing clinical studies across all phases of research and

discovery, development, validation and approval.

28 March 2024

Amarex to Exhibit at the Maryland Business Showcase | March 28 | Laurel, MD

Germantown, MD, USA (March 18, 2024) – Amarex Clinical Research, LLC, an NSF Company, is pleased to announce it will exhibit at the Maryland Tech Council (MTC) Maryland Business Showcase on Thursday, March 28 at 5:30 PM at the Maryland Jockey Club in Laurel, MD.

23 February 2024

Amarex Client Receives U.S. FDA Marketing Approval for Hemoconcentrators 

Germantown, MD, USA (February 23, 2024) – Amarex Clinical Research, LLC, an NSF company is pleased to announce its client Tecnoideal America, Inc. received U.S. FDA 510(k) clearance for hemoconcentrators used in adult patients during or after cardiopulmonary bypass surgery to remove excess fluids from the blood and restore physiological blood conditions. This product successfully completed performance and substantial equivalence testing, and the data proved the device to be substantially equivalent to the predicate device. 

02 February 2024

Amarex Celebrates Its 25th Anniversary!

Germantown, MD, USA (February 02, 2024) – Amarex Clinical Research, LLC, an NSF company, announces December 2023 marked its 25th year advancing patient access to safe and effective clinical products through delivery of outstanding regulatory and clinical trial services to Sponsors within the life sciences industry.

20220218 picture 1_edited.jpg
17 February 2022

Amarex Taiwan Chief Operating Officer, Dr. Chia-Hua Maggie Ho, Featured in 2021 End-of-year Global Bio Investment Article: Bringing U.S. FDA Review Criteria to the Taiwanese Biotech Industry

Taipei, Taiwan (February 17) - Many non-COVID-19 global clinical trials are delayed or terminated early due to the COVID-19 pandemic. The clinical trials carried out by Amarex were not forced to be suspended or terminated during the pandemic. Amarex set up the monitoring plan and audit system remotely and that not only overcomes the difficulty of on-site monitoring but also ensures the quality of clinical trials and the safety and rights of subjects.

02 November 2021

Amarex Taiwan Exhibiting at BIO Asia-Taiwan 2021 | Nov. 4-7 | Taipei, Taiwan

​Taipei, Taiwan (November 02, 2021) – We are pleased to announce that Amarex Taiwan, LLC is exhibiting at BIO Asia-Taiwan 2021, held November 4-7 at the Taipei Nangang Exhibition Center in Taiwan.

16 September2021

Amarex Passes Taiwan FDA GTP Audit: Result is a Resounding No Findings

Taipei, Taiwan (September 16, 2021) – Amarex Taiwan, LLC announces a no findings result of a Taiwan Food and Drug Administration (TFDA) audit of its office last month.

Covid 19
24 February 2021

Amarex Featured in 15-year Anniversary Issue of the NSF International Journal

The just released Issue 48 of NSF International’s Health Science Journal features contributions by Amarex. The journal is available at

Young Businesswoman
15 February 2021

Amarex Job Openings at the BioCapital Life Sciences Career Fair | Feb. 18, 2021

We are featuring current job openings at the MD Tech Council BioCapital Life Sciences Career Fair, Thursday, February 18th. This virtual event is free and open to all students and job seekers interested in career opportunities in the life sciences industry. Register for this virtual event, visit our booth, and speak to an Amarex representative about expanding your career:

25 January 2021

Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials

On January 07, Dr. Kazem Kazempour, President & CEO, conducted the webinar Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials. View the full webinar recording on our YouTube channel.

  • LinkedIn Social Icon
  • Facebook
  • Twitter
  • YouTube

Recommended by the people who matter most: our clients.

Chief Medical Officer

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.



Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.



bottom of page